RE:To do list ...MrMugsy wrote: Items still outstanding for 2022 ...
1. IBD update (calendar Q4)
2. Presentation upate (assuming it follows the IBD update)
3. Animal Studies to lead to acute/chronic dosing paths (Dec 2022 - Jan 2023)
-------------------------
Had an interesting discussion about IBD with insiders. Will discuss that in more detail as we go.
What it seems we're looking at here is an attempt to reduce gut inflammation as much as possible. cut off other inflammatory diseases at the source.
Then ... we can branch out from there.
https://www.mdpi.com/2227-9059/10/1/85/htm
Thanks for posting Mugsy. I wonder if ATE is thinking oxidative stress (OS).
IBD is closely associated with OS. OS stems from excessive reactive oxygen species (ROS) and can lead to cell impairment. One way to tackle OS is by way of antioxidants which mitigate the effects of ROS. This can be done more effectively with the use of nano technology. This two-pronged approach is referred to as antioxidative nanotherapeutics and could lead to an effective treatment for IBD. Ref provides an overview (quite technical).
There is increasing interest in the OS space as a therapeutic approach to IBD and other indications. Scientists have recently synthesized several related compounds, including persulfide prodrugs and precursors by the unnamed American 'nano' chemist (assuming he is the same guy).
From one of many scientific papers (Mar 2021): "In summary, based on the current scientific knowledge, it can be assumed that future therapy with antioxidants as an add-on therapy or independent medical options of treatment will become the strategy of choice in IBD." One might add that antioxidants as an add-on therapy to Oten also might be a solution to Oten chronic LTEs.
Just speculation. Well ouside of my sandbox. But it seems to tie in with your discussion with ATE.